Inhibitor to factor IX following activated prothrombin-complex concentrate treatment.
D000917:Antibody Formation; D001688:Biological Products / Q000009:adverse effects; D005164:Factor IX / Q000276:immunology*; D006467:Hemophilia A / Q000628:therapy; D006801:Humans; D011516:Prothrombin / Q000009:adverse effects*
D001688:Biological Products; D011516:Prothrombin; D005164:Factor IX